Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 1 |
2020 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following terms were ignored: %, %
The following terms were not found in PubMed: 5BAuth
Page 1
Obesity reduced survival with 5-fluorouracil and did not protect against chemotherapy-induced cachexia or immune cell cytotoxicity in mice.
Cancer Biol Ther. 2022 Dec 31;23(1):1-15. doi: 10.1080/15384047.2022.2108306.
Cancer Biol Ther. 2022.
PMID: 35968771
Free PMC article.
C56BL/6 mice were given high fat (Obese) or standard diets (Lean) for 4 months and then subjected to three cycles of 5FU (5d-40 mg/kg Lean Mass, 9d rest) or PBS vehicle control. Shockingly, only 60% of Obese survived 3 cycles compared to 100% of Lean, and Obese lost signif …
C56BL/6 mice were given high fat (Obese) or standard diets (Lean) for 4 months and then subjected to three cycles of 5FU (5d-40 mg/kg …
Adiposity and Fat-Free Mass of Children Born with Very Low Birth Weight Do Not Differ in Children Fed Supplemental Donor Milk Compared with Those Fed Preterm Formula.
McGee M, Unger S, Hamilton J, Birken CS, Pausova Z, Kiss A, Bando N, O'Connor DL.
McGee M, et al.
J Nutr. 2020 Feb 1;150(2):331-339. doi: 10.1093/jn/nxz234.
J Nutr. 2020.
PMID: 31599955
Free article.
Item in Clipboard
Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus.
Pavel M, Unger N, Borbath I, Ricci S, Hwang TL, Brechenmacher T, Park J, Herbst F, Beaumont JL, Bechter O.
Pavel M, et al.
Target Oncol. 2016 Oct;11(5):667-675. doi: 10.1007/s11523-016-0440-y.
Target Oncol. 2016.
PMID: 27193465
Clinical Trial.
HRQOL was assessed at baseline, for three 28-day cycles, and then at every three cycles until end of treatment (EOT) with EQ-5D, EORTC QLQ-C30, and EORTC QLQ-GINET21 instruments. RESULTS: The most common grade 3 or 4 AEs included hyperglycemia, infections, stomatitis, fati …
HRQOL was assessed at baseline, for three 28-day cycles, and then at every three cycles until end of treatment (EOT) with EQ-5D, EORT …
Item in Clipboard
Cite
Cite